Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Список исп. литературыСкрыть список 1. American Psychiatric Association Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association. Audinot V, Mailliet F, Lahaye-Brasseur C et al. New selective ligands of human cloned melatonin MT1 and MT2 recept 2000. Naunyn Schmiedebergs Arch Pharmacol 2003; 367: 553–61. 2. Bertaina-Anglade V, Drieu RC, Boyer PA, Mocaer E. Antidepressant-like effects of agomelatine (S20098) in the learned helplessness model. Behav Pharmacol 2006; 17: 703–13. 3. Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373: 746–58. 4. Committee for Proprietary Medicinal Products Note for guidance on clinical investigation of medicinal products in the treatment of depression 2002. CPMP/EWP/518/97.Available at: www.emea.europa.eu/pdfs/human/ewp/ 051897en.pdf 5. Dubocovich ML. Drug evaluation: agomelatine targets a range of major depressive disorder symptoms. Curr Opin Investig Drugs 2006; 7: 670–80. 6. Emens J, Lewy A, Kinzie JM et al. Circadian misalignment in major depressive disorder. Psychiatry Res 2009; 168: 259–61. 7. European Medicines Agency European Public Assessment Report. Valdoxan 2009. Available at: http://www.emea.europa.eu/humandocs/Humans/EPAR/valdoxan/valdoxan.htm 8. Fuchs E, Schmelting B, Mocaer E. Effects of the novel antidepressant agomelatine (S20098) and fluoxetine in chronically stressed tree shrews, an animal model of depression. Eur Neuropsychopharmacol 2006; 16: 338–9. 9. Goodwin GM, Emsley R, Rembry S, Rouillon F. Agomelatine prevents relapse in patients with major depressive disorder, without evidence of discontinuation syndrome. J Clin Psychiatry 2009; 70: 1128–37. 10. Guy W. ECDEU assessment manual for psychopharmacology. Revision ed. US Department of Health, Education, and Welfare (ADM) 756–338. Rockville, MD: National Institute of Mental Health 1976. 11. Hamilton M. A rating scale for anxiety. J Neurol Neurosurg Psychiatry 1959; 23: 56–62. 12. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278–96. 13. Hansen RA, Gartlehner G, Lohr KN et al. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005; 143: 415–26. 14. Kasper S, Hajak G, Wulff K et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle, depressive and anxiety symptoms in patients with major depressive disorder. A randomized, double-blind comparison with sertraline. J Clin Psychiatry 2010; 71: 109–20. 15. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006; 16: 93–100. 16. Kennedy SH, Rizvi SJ. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs 2010; 24: 479–99. 17. Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry 2000; 57: 311–7. 18. Kirsch I, Moore TJ, Scoboria A, Nicholls SS. The emperor’s new drugs: an analysis of antidepressant medication data submitted to the US Food and Drug Administration. Prev Treat 2002; 5: 1–14. 19. Krauchi K, Cajochen C, Mori D et al. Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature. Am J Physiol 1997; 272: 1178–88. 20. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007; 68: 1723–32. 21. Leproult R, Van Onderbergen A, L’Hermite-Baleriaux M et al. Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol (Oxf) 2005; 63: 298–304. 22. Loo H, Hale A, Dhaenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002; 17: 239–47. 23. Melander H, Salmonson T, Abadie E, van Zwieten-Boot B. A regulatory Apologia-a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol 2008; 18: 623–7. 24. Millan MJ, Brocco M, Gobert A, Dekeyne A. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic proper ties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl) 2005; 177: 448–58. 25. Montgomery SA, Lecrubier Y. Is severe depression a separate indication? ECNP Consensus Meeting Sept. 20 1996; Amsterdam. European College of Neuropsychopharmacology. Eur Neuropsychopharmacol 1999; 9: 259–64. 26. Montgomery SA, Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 2007; 22: 283–91. 27. Montgomery SA, Kennedy SH, Burrows GD et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebocontrolled discontinuation study. Int Clin Psychopharmacol 2004; 19: 271–80. 28. Montgomery SA, Baldwin DS, Blier P et al. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 2007; 22: 323–9. 29. Nemeroff CB, Thase ME. A double-blind, placebocontrolled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. J Psychiatr Res 2007; 41: 351–9. 30. Nemeroff CB, Entsuah R, Benattia I et al. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry 2008; 63: 424–34. 31. Ohayon MM, Roth T. Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr Res 2003; 37: 9–15. 32. Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007; 10: 661–73. 33. Papakostas GI, Thase ME, Fava M et al. Are antidepressant drugs that combine serotonergic and noradrenergic mechan isms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 2007; 62: 1217–27. 34. Papp M, Gruca P, Boyer PA, Mocaer E. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 2003; 28: 694–703. 35. Peeters F, Berkhof J, Delespaul P et al. Diurnal mood variation in major depressive disorder. Emotion 2006; 6: 383–91. 36. Quera Salva MA, Vanier B, Laredo J et al. Major depressive disorder, sleep EEG, and agomelatine: an open-label study. Int J Neuropsychopharmacol 2007; 10: 691–6. 37. Reynolds JEF. Martindale, the extra pharmacopoeia. 31st ed. London, UK: Royal Pharmaceutical Society 1996. 38. Ruhe HG, Dekker JJ, Peen J et al. Clinical use of the Hamilton depression rating scale: is increased efficiency possible? A post hoc comparison of Hamilton depression rating scale, Maier and Bech subscales, Clinical global impression, and symptom checklist-90 scores. Compr Psychiatry 2005; 46: 417–27. 39. Santen G, Gomeni R, Danhof M, Pasqua OD. Sensitivity of the individual items of the Hamilton depression rating scale to response and its consequences for the assessment of efficacy. J Psychiatr Res 2008; 42: 1000–9. 40. Sheehan DV, Lecrubier Y, Harnett Sheehan K et al. The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. Eur Psychiatry 1997; 12: 232–41. 41. Souetre E, Salvati E, Belugou JL et al. Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality. Psychiatry Res 1989; 28: 263–78. 42. Soumier A, Banasr M, Lortet S et al. Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. Neuropsychopharmacology 2009; 34: 2390–403. 43. Spalletta G, Pasini A, Caltagirone C. Fluoxetine alone in the treatment of first episode anxious-depression: an open clinical trial. J Clin Psychopharmacol 2002; 22: 263–6. 44. Stephenson DA, Harris B, Davies RH et al. The impact of antidepressants on sleep and anxiety: a comparative study of fluoxetine and dothiepin using the Leeds Sleep Evaluation Questionnaire. Hum Psychopharmacol 2000; 15: 529–34. 45. Yous S, Andrieux J, Howell HE et al. Novel naphthalenic ligands with high affinity for the melatonin receptor. J Med Chem 1992; 35: 1484–6.